The attempted merger between leading biopharma data provider IQVIA and pharma ad specialist DeepIntent has been put on ice after continued scrutiny from the U.S. government. In 2022, IQVIA attempted ...

IQVIA Holdings Inc. (NYSE:IQV), a global leader in advanced analytics, technology solutions, and clinical research services ...

How little noise did IQVIA make about its recent highly significant acquisition of Throtle? The change in ownership is noted in a single sentence on the “About” page on Throtle’s website: “Throtle Inc ...

I rate IQVIA as a hold due to long-term competitive threats, particularly from one player, and concerns about capital allocation and high debt. IQVIA's business model is solid, but declining gross ...

IQVIA provides a broad range of services to biopharma customers, including outsourced R&D services in support of clinical trials. Recent spending caution and the end of COVID-related revenue have led ...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of AI-powered analytics, technology solutions and clinical research services to the healthcare and life ...

"IQVIA delivered strong revenue and profit performance, at the high-end of our expectations," said Ari Bousbib, chairman and CEO of IQVIA. "In the clinical trial business, we experienced delayed ...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the ...